Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
News
Blood Cancer United Applauds Passage of Vital Policies to Support Kids with Cancer
Children with cancer will soon have faster access to critical care
News
FDA Approves Combination Therapy for Newly Diagnosed Multiple Myeloma
“This approval represents an important step forward for people who are newly diagnosed with this disease,” said Lore Gruenbaum, Ph.D., Chief Scientifi…
News
GiveByCruising Partners with Blood Cancer United to Advance Blood Cancer Research
GiveByCruising by Dream Vacations is proudly partnering with Blood Cancer United® by donating 70% of its booking commissions over the next five years …
Research
Blood cancer research 2026: Meeting patients where they want to be
Today, Blood Cancer United has two main goals for the research we fund. The search for cures for every form of blood cancer continues. But with so man…
News
Blood Cancer United Expands its Beat AML® Master Clinical Trial Advancing Next-Generation Treatment
In collaboration with AVEO Oncology, an LG Chem company, (“AVEO”) the new Beat AML sub-study is evaluating ficlatuzumab, a monoclonal antibody targeti…
News
FDA Approval Increases Access to a Follicular Lymphoma Immunotherapy
The FDA approves Lunsumio VELO™, a one-minute injection for relapsed follicular lymphoma, showing strong response rates and improved patient access.
News
Chief Executive Officer of BDO USA to Receive 2026 James L. Eichberg Lifetime Achievement Award
Blood Cancer United ®, formerly The Leukemia & Lymphoma Society, has named Mr. Wayne Berson, Chief Executive Officer of BDO USA, the recipient of the …
News
FDA Expands Use of Targeted Therapy for Most Common Leukemia in Adults
The FDA this week approved pirtobrutinib (Jaypirca®) for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in ad…
News
FDA Approves First CAR T-Cell Immunotherapy for Marginal Zone Lymphoma
Liso-cel (Breyanzi®) is now approved to treat five types of blood cancer
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
